Treatment

Error in the dosage of Methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Dennis Scheicht

Annals of the Rheumatic Diseases Jun 2022, 81 (6) e89; DOI: 10.1136/annrheumdis-2020-217041
Treatment of lupus: more options after a long wait
Myrto Kostopoulou, Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas

Annals of the Rheumatic Diseases Jun 2022, 81 (6) 753-756; DOI: 10.1136/annrheumdis-2021-221817
Secukinumab efficacy in patients with PsA is not dependent on patients’ body mass index
Ilenia Pantano, Daniela Iacono, Ennio Giulio Favalli, Giuseppe Scalise, Luisa Costa, Francesco Caso, Giuliana Guggino, Raffaele Scarpa, Francesco Ciccia

Annals of the Rheumatic Diseases Mar 2022, 81 (3) e42; DOI: 10.1136/annrheumdis-2020-217251
Comments on the article: “Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial”
Mohammad Reza Mousavi, Erfan Taherifard

Annals of the Rheumatic Diseases Mar 2022, 81 (3) e46; DOI: 10.1136/annrheumdis-2020-217287
Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis
Motohisa Yamamoto, Noritada Yoshikawa, Hirotoshi Tanaka

Annals of the Rheumatic Diseases Mar 2022, 81 (3) e50; DOI: 10.1136/annrheumdis-2020-217076
Response to: ‘The cost of arthralgia ‘pretreatment’ to prevent rheumatoid arthritis’ by Rothschild
Annette van der Helm-van Mil, Robert BM Landewé

Annals of the Rheumatic Diseases Feb 2022, 81 (2) e19; DOI: 10.1136/annrheumdis-2020-216984
Response to: ‘Dupilumab as a potential steroid-sparing treatment for IgG4-related disease’ by Della-Torre et al
Rachel S Simpson, Jason K Lee

Annals of the Rheumatic Diseases Feb 2022, 81 (2) e25; DOI: 10.1136/annrheumdis-2020-216955
Interleukin-4 as an emerging therapeutic target for IgG4-related disease
Mitsuhiro Akiyama, Yuko Kaneko, Tsutomu Takeuchi

Annals of the Rheumatic Diseases Feb 2022, 81 (2) e28; DOI: 10.1136/annrheumdis-2020-216961
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease
Corrado Campochiaro, Giulio Cavalli, Nicola Farina, Alessandro Tomelleri, Giacomo De Luca, Lorenzo Dagna

Annals of the Rheumatic Diseases Jan 2022, 81 (1) e11; DOI: 10.1136/annrheumdis-2019-216610
Response to: ‘Frequency of MRI changes suggestive of axial spondyloarthritis in the axial in a large population-based cohort of individuals aged <45 years’ by Parperis
Xenofon Baraliakos, Adrian Richter, Carsten O Schmidt, Juergen Braun

Annals of the Rheumatic Diseases Jan 2022, 81 (1) e8; DOI: 10.1136/annrheumdis-2019-216798

Main menu

Treatment

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Treatment

Pages